Mark A. Glickman

Mark A. Glickman discloses dealings in 4 companies, chiefly Aralez Pharmaceuticals Inc., MetaVia Inc. and Esperion Therapeutics, Inc. We count 12 filings; the first trade dates from 5 February 2016 and the latest from 30 June 2025.

On the open market, the record shows 1 purchase worth €81k and 1 sale worth €7,925. The net balance comes to €73k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 8 share grants and 1 option exercise.

The latest filing, published on 1 July 2025, reports a share grant in MetaVia Inc. The last purchase on record was published on 18 May 2016, which is 3,808 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.